LA JOLLA, Calif.,
For the year ended
"We were able to significantly control costs in 2007 and appreciated the
advances from affiliates," noted
Research suggests that SF-1019 has analgesic properties with a perceived
ability to reduce the inflammation present in a number of clinical conditions
including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS)
and other auto-immune and neurological disorders. A recent, limited proof of
concept trial for SF-1019 in
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation
(OTC Bulletin Board: IMYN) plans to market and distribute life enhancing
therapeutics. Currently, the company has exclusive worldwide rights from its
largest shareholder, Argyll Biotechnologies, LLC, to market, sell and
distribute SF-1019, a compound that was developed from extensive research into
Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has
initiated the process for regulatory approval of SF-1019 in several countries
and preparations for clinical trials are underway in both the US and
The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-KSB for its most recent fiscal year recently filed with SEC. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.
SOURCE Immunosyn Corporation